AOD-9604 vs GH Fragments: Lipolysis Research Without Full GH Signaling

Background

Full-length human growth hormone (hGH, 191 amino acids) produces a complex set of biological effects: anabolic signaling via hepatic IGF-1 generation, direct metabolic effects on adipose and muscle, diabetogenic effects via insulin resistance, and growth-promoting effects on bone and cartilage. From a research perspective, this broad activity makes hGH an imprecise tool for isolating lipolysis mechanisms.

In the 1990s, researchers identified that the C-terminal region of hGH (residues 176–191) retained lipolytic activity but lacked the anabolic, IGF-1-generating, and glucose-dysregulating effects of the full protein. AOD-9604 is a modified version of this fragment designed for research and eventual therapeutic investigation.

Molecular profile

• Sequence: based on hGH(177–191) with an added N-terminal tyrosine (Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, 16 aa)
• Molecular weight: ~1,817 Da
• Modification: disulfide bond between Cys-7 and Cys-14
• CAS: 221231-10-3

Mechanism

AOD-9604's lipolytic mechanism differs from full-length hGH's:

• Does not activate the growth hormone receptor in standard assays
• Does not elevate IGF-1 in published studies
• Proposed to act through a distinct receptor or mechanism that stimulates hormone-sensitive lipase (HSL) activity in adipocytes
• Upregulates β3-adrenergic receptor expression and responsiveness in some adipose tissue models
• Inhibits lipogenesis in parallel with promoting lipolysis

This mechanistic separation is the scientific rationale for AOD-9604 as a research tool: it allows investigators to probe adipose tissue biology without the confounding anabolic, glycemic, and growth-promoting effects of full hGH.

What laboratories typically study

• Adipocyte lipolysis assays — free fatty acid release from 3T3-L1 or primary adipocytes
• Hormone-sensitive lipase activity — phospho-HSL immunoblots, enzymatic assays
• Adipogenesis and lipogenesis — preadipocyte differentiation, lipid accumulation (Oil Red O), lipogenic gene expression (FAS, ACC, SREBP1c)
• β-adrenergic receptor biology — receptor density, coupling efficiency, catecholamine response
• Obesity models — DIO rodent adipose tissue characterization, metabolic parameters without confounding IGF-1 elevation
• Comparative pharmacology — AOD-9604 vs recombinant hGH on lipolysis-specific endpoints
• Cartilage research — some studies explore fragment effects on chondrocyte biology independent of systemic IGF-1

What AOD-9604 is not

Worth clarifying given marketing claims in non-research contexts:

• Not equivalent to hGH — lacks IGF-1-generating and anabolic effects
• Not a GH secretagogue — does not stimulate pituitary GH release
• Not a myostatin inhibitor or direct muscle-growth agent

Its research value is specifically its adipose-selective profile.

Handling and quality

• Supplied as lyophilized powder (typical format 5 mg)
• Store lyophilized at -20°C, protected from light
• Reconstitute with sterile/bacteriostatic water
• Disulfide bond integrity is important — avoid harsh reducing conditions during reconstitution
• Reconstituted stability ~4 weeks at 2–8°C
• Verify by HPLC (≥99.0%) with MS identity; obtain batch-specific COA

Related reading

• /research/aod-9604 — compound profile
• /blog/aod-9604-precision-lipolysis-research — focused AOD-9604 overview
• /category/weight-loss-research — broader category
• /guides/how-to-read-peptide-coa — batch documentation

RUO disclaimer

For laboratory research use only. Not intended to diagnose, treat, cure, or prevent any disease. Not for human consumption outside approved research settings.